DGX 10-Q Quarterly Report Sept. 30, 2022 | Alphaminr
QUEST DIAGNOSTICS INC
ALPHAMINR

DGX 10-Q Quarter ended Sept. 30, 2022

Balance Sheet
Cash Flow
Income Statement
QUEST DIAGNOSTICS INC
10-Qs and 10-Ks
10-Q
 		Quarter ended March 31, 2025
10-K
 		Fiscal year ended Dec. 31, 2024
10-Q
 		Quarter ended Sept. 30, 2024
10-Q
 		Quarter ended June 30, 2024
10-Q
 		Quarter ended March 31, 2024
10-K
 		Fiscal year ended Dec. 31, 2023
10-Q
 		Quarter ended Sept. 30, 2023
10-Q
 		Quarter ended June 30, 2023
10-Q
 		Quarter ended March 31, 2023
10-K
 		Fiscal year ended Dec. 31, 2022
10-Q
 		Quarter ended Sept. 30, 2022
10-Q
 		Quarter ended June 30, 2022
10-Q
 		Quarter ended March 31, 2022
10-K
 		Fiscal year ended Dec. 31, 2021
10-Q
 		Quarter ended Sept. 30, 2021
10-Q
 		Quarter ended June 30, 2021
10-Q
 		Quarter ended March 31, 2021
10-K
 		Fiscal year ended Dec. 31, 2020
10-Q
 		Quarter ended Sept. 30, 2020
10-Q
 		Quarter ended June 30, 2020
10-Q
 		Quarter ended March 31, 2020
10-K
 		Fiscal year ended Dec. 31, 2019
10-Q
 		Quarter ended Sept. 30, 2019
10-Q
 		Quarter ended June 30, 2019
10-Q
 		Quarter ended March 31, 2019
10-K
 		Fiscal year ended Dec. 31, 2018
10-Q
 		Quarter ended Sept. 30, 2018
10-Q
 		Quarter ended June 30, 2018
10-Q
 		Quarter ended March 31, 2018
10-K
 		Fiscal year ended Dec. 31, 2017
10-Q
 		Quarter ended Sept. 30, 2017
10-Q
 		Quarter ended June 30, 2017
10-Q
 		Quarter ended March 31, 2017
10-K
 		Fiscal year ended Dec. 31, 2016
10-Q
 		Quarter ended Sept. 30, 2016
10-Q
 		Quarter ended June 30, 2016
10-Q
 		Quarter ended March 31, 2016
10-K
 		Fiscal year ended Dec. 31, 2015
10-Q
 		Quarter ended Sept. 30, 2015
10-Q
 		Quarter ended June 30, 2015
10-Q
 		Quarter ended March 31, 2015
10-K
 		Fiscal year ended Dec. 31, 2014
10-Q
 		Quarter ended Sept. 30, 2014
10-Q
 		Quarter ended June 30, 2014
10-Q
 		Quarter ended March 31, 2014
10-K
 		Fiscal year ended Dec. 31, 2013
10-Q
 		Quarter ended Sept. 30, 2013
10-Q
 		Quarter ended June 30, 2013
10-Q
 		Quarter ended March 31, 2013
10-K
 		Fiscal year ended Dec. 31, 2012
10-Q
 		Quarter ended Sept. 30, 2012
10-Q
 		Quarter ended June 30, 2012
10-Q
 		Quarter ended March 31, 2012
10-K
 		Fiscal year ended Dec. 31, 2011
10-Q
 		Quarter ended Sept. 30, 2011
10-Q
 		Quarter ended June 30, 2011
10-Q
 		Quarter ended March 31, 2011
10-K
 		Fiscal year ended Dec. 31, 2010
10-Q
 		Quarter ended Sept. 30, 2010
10-Q
 		Quarter ended June 30, 2010
10-Q
 		Quarter ended March 31, 2010
10-K
 		Fiscal year ended Dec. 31, 2009
PROXIES
DEF 14A
 		Filed on April 4, 2025
DEF 14A
 		Filed on April 5, 2024
DEF 14A
 		Filed on April 6, 2023
DEF 14A
 		Filed on April 19, 2022
DEF 14A
 		Filed on April 9, 2021
DEF 14A
 		Filed on April 8, 2020
DEF 14A
 		Filed on April 3, 2019
DEF 14A
 		Filed on April 4, 2018
DEF 14A
 		Filed on April 5, 2017
DEF 14A
 		Filed on April 7, 2016
DEF 14A
 		Filed on April 10, 2015
DEF 14A
 		Filed on April 8, 2014
DEF 14A
 		Filed on April 10, 2013
DEF 14A
 		Filed on March 28, 2012
DEF 14A
 		Filed on April 5, 2011
DEF 14A
 		Filed on April 2, 2010
dgx-20220930
0001022079 12/31 2022 Q3 FALSE 0001022079 2022-01-01 2022-09-30 0001022079 2022-10-14 xbrli:shares 0001022079 2022-07-01 2022-09-30 iso4217:USD 0001022079 2021-07-01 2021-09-30 0001022079 2021-01-01 2021-09-30 iso4217:USD xbrli:shares 0001022079 2022-09-30 0001022079 2021-12-31 0001022079 2020-12-31 0001022079 2021-09-30 0001022079 us-gaap:CommonStockMember 2022-06-30 0001022079 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001022079 us-gaap:RetainedEarningsMember 2022-06-30 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001022079 us-gaap:TreasuryStockMember 2022-06-30 0001022079 us-gaap:NoncontrollingInterestMember 2022-06-30 0001022079 2022-06-30 0001022079 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001022079 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001022079 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001022079 us-gaap:TreasuryStockMember 2022-07-01 2022-09-30 0001022079 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001022079 us-gaap:CommonStockMember 2022-09-30 0001022079 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001022079 us-gaap:RetainedEarningsMember 2022-09-30 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001022079 us-gaap:TreasuryStockMember 2022-09-30 0001022079 us-gaap:NoncontrollingInterestMember 2022-09-30 0001022079 us-gaap:CommonStockMember 2021-12-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001022079 us-gaap:RetainedEarningsMember 2021-12-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001022079 us-gaap:TreasuryStockMember 2021-12-31 0001022079 us-gaap:NoncontrollingInterestMember 2021-12-31 0001022079 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001022079 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-09-30 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001022079 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001022079 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001022079 us-gaap:TreasuryStockMember 2022-01-01 2022-09-30 0001022079 us-gaap:CommonStockMember 2021-06-30 0001022079 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001022079 us-gaap:RetainedEarningsMember 2021-06-30 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001022079 us-gaap:TreasuryStockMember 2021-06-30 0001022079 us-gaap:NoncontrollingInterestMember 2021-06-30 0001022079 2021-06-30 0001022079 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001022079 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001022079 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001022079 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0001022079 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001022079 us-gaap:CommonStockMember 2021-09-30 0001022079 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001022079 us-gaap:RetainedEarningsMember 2021-09-30 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001022079 us-gaap:TreasuryStockMember 2021-09-30 0001022079 us-gaap:NoncontrollingInterestMember 2021-09-30 0001022079 us-gaap:CommonStockMember 2020-12-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001022079 us-gaap:RetainedEarningsMember 2020-12-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001022079 us-gaap:TreasuryStockMember 2020-12-31 0001022079 us-gaap:NoncontrollingInterestMember 2020-12-31 0001022079 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001022079 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-09-30 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0001022079 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001022079 us-gaap:TreasuryStockMember 2021-01-01 2021-09-30 0001022079 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001022079 dgx:PackHealthLLCMember 2022-02-01 2022-02-01 0001022079 dgx:PackHealthLLCMember 2022-02-01 0001022079 dgx:PackHealthLLCMember us-gaap:CustomerRelationshipsMember 2022-02-01 2022-02-01 0001022079 dgx:LabtechDiagnosticsLLCMember 2022-01-01 2022-09-30 0001022079 dgx:LabtechDiagnosticsLLCMember us-gaap:CustomerRelationshipsMember 2022-01-01 2022-09-30 0001022079 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember dgx:Q2SolutionsMember 2021-04-01 xbrli:pure 0001022079 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember dgx:Q2SolutionsMember 2021-04-01 2021-04-01 0001022079 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember dgx:Q2SolutionsMember us-gaap:OtherIncomeMember 2021-04-01 2021-06-30 0001022079 dgx:ForeignCurrencyTranslationMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember dgx:Q2SolutionsMember 2021-04-01 2021-06-30 0001022079 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember dgx:Q2SolutionsMember 2021-04-01 2021-06-30 0001022079 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001022079 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001022079 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001022079 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001022079 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001022079 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001022079 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001022079 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001022079 dgx:PackHealthLLCAndLabtechDiagnosticsLLCMember 2022-09-30 0001022079 dgx:PackHealthLLCAndLabtechDiagnosticsLLCMember dgx:MeasurementInputComparableCompanyRevenueVolatilityMember 2022-09-30 0001022079 us-gaap:MeasurementInputDiscountRateMember dgx:PackHealthLLCAndLabtechDiagnosticsLLCMember srt:MinimumMember 2022-09-30 0001022079 us-gaap:MeasurementInputDiscountRateMember dgx:PackHealthLLCAndLabtechDiagnosticsLLCMember srt:MaximumMember 2022-09-30 0001022079 us-gaap:FairValueInputsLevel3Member dgx:ContingentConsiderationMember 2021-12-31 0001022079 us-gaap:FairValueInputsLevel3Member dgx:ContingentConsiderationMember 2022-01-01 2022-09-30 0001022079 us-gaap:FairValueInputsLevel3Member dgx:ContingentConsiderationMember 2022-09-30 0001022079 dgx:UMassJointVentureMember 2015-07-01 0001022079 2021-01-01 2021-12-31 0001022079 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-09-30 0001022079 us-gaap:CustomerRelationshipsMember 2022-09-30 0001022079 us-gaap:CustomerRelationshipsMember 2021-12-31 0001022079 us-gaap:NoncompeteAgreementsMember 2022-01-01 2022-09-30 0001022079 us-gaap:NoncompeteAgreementsMember 2022-09-30 0001022079 us-gaap:NoncompeteAgreementsMember 2021-12-31 0001022079 us-gaap:UnpatentedTechnologyMember 2022-01-01 2022-09-30 0001022079 us-gaap:UnpatentedTechnologyMember 2022-09-30 0001022079 us-gaap:UnpatentedTechnologyMember 2021-12-31 0001022079 us-gaap:OtherIntangibleAssetsMember 2022-01-01 2022-09-30 0001022079 us-gaap:OtherIntangibleAssetsMember 2022-09-30 0001022079 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0001022079 dgx:TotalAmortizingIntangibleAssetsMember 2022-01-01 2022-09-30 0001022079 dgx:TotalAmortizingIntangibleAssetsMember 2022-09-30 0001022079 dgx:TotalAmortizingIntangibleAssetsMember 2021-12-31 0001022079 us-gaap:TradeNamesMember 2022-09-30 0001022079 us-gaap:TradeNamesMember 2021-12-31 0001022079 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2022-09-30 0001022079 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2021-12-31 0001022079 us-gaap:LongTermDebtMember us-gaap:FairValueHedgingMember 2022-09-30 0001022079 us-gaap:LongTermDebtMember us-gaap:FairValueHedgingMember 2021-12-31 0001022079 2022-01-01 2022-03-31 0001022079 2022-04-01 2022-06-30 0001022079 2021-10-01 2021-12-31 0001022079 2021-04-01 2021-06-30 0001022079 2021-01-01 2021-03-31 0001022079 2022-02-01 2022-02-01 0001022079 us-gaap:TreasuryStockMember dgx:AcceleratedShareRepurchaseAgreementsMember 2021-01-01 2021-09-30 0001022079 dgx:AcceleratedShareRepurchaseAgreementsMember 2021-04-01 2021-04-30 0001022079 dgx:AcceleratedShareRepurchaseAgreementsMember 2021-01-01 2021-09-30 0001022079 dgx:AmendedRealEstateLeaseMember 2022-09-30 0001022079 us-gaap:LetterOfCreditMember us-gaap:SecuredDebtMember 2022-09-30 0001022079 us-gaap:SecuredDebtMember 2022-09-30 0001022079 us-gaap:LetterOfCreditMember dgx:SeniorunsecuredrevolvingcreditfacilityMember 2022-09-30 0001022079 dgx:SeniorunsecuredrevolvingcreditfacilityMember 2022-09-30 0001022079 dgx:A401kPlanLawsuitMember us-gaap:PendingLitigationMember 2020-10-31 dgx:claim 0001022079 us-gaap:PendingLitigationMember dgx:DataSecurityIncidentMember 2022-09-30 0001022079 dgx:ExcludesgeneralandprofessionalliabilityclaimsMember 2022-09-30 0001022079 dgx:ExcludesgeneralandprofessionalliabilityclaimsMember 2021-12-31 0001022079 srt:MinimumMember dgx:DiagnosticInformationServicesBusinessMember 2021-01-01 2021-09-30 0001022079 srt:MinimumMember dgx:DiagnosticInformationServicesBusinessMember 2022-01-01 2022-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2022-07-01 2022-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2021-07-01 2021-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2022-01-01 2022-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2021-01-01 2021-09-30 0001022079 us-gaap:AllOtherSegmentsMember 2022-07-01 2022-09-30 0001022079 us-gaap:AllOtherSegmentsMember 2021-07-01 2021-09-30 0001022079 us-gaap:AllOtherSegmentsMember 2022-01-01 2022-09-30 0001022079 us-gaap:AllOtherSegmentsMember 2021-01-01 2021-09-30 0001022079 us-gaap:CorporateMember 2022-07-01 2022-09-30 0001022079 us-gaap:CorporateMember 2021-07-01 2021-09-30 0001022079 us-gaap:CorporateMember 2022-01-01 2022-09-30 0001022079 us-gaap:CorporateMember 2021-01-01 2021-09-30 0001022079 dgx:RoutineClinicalTestingAndOtherServicesMember 2022-07-01 2022-09-30 0001022079 dgx:RoutineClinicalTestingAndOtherServicesMember 2021-07-01 2021-09-30 0001022079 dgx:RoutineClinicalTestingAndOtherServicesMember 2022-01-01 2022-09-30 0001022079 dgx:RoutineClinicalTestingAndOtherServicesMember 2021-01-01 2021-09-30 0001022079 dgx:COVID19TestingServicesMember 2022-07-01 2022-09-30 0001022079 dgx:COVID19TestingServicesMember 2021-07-01 2021-09-30 0001022079 dgx:COVID19TestingServicesMember 2022-01-01 2022-09-30 0001022079 dgx:COVID19TestingServicesMember 2021-01-01 2021-09-30 0001022079 dgx:GenebasedandesoterictestingservicesMember 2022-07-01 2022-09-30 0001022079 dgx:GenebasedandesoterictestingservicesMember 2021-07-01 2021-09-30 0001022079 dgx:GenebasedandesoterictestingservicesMember 2022-01-01 2022-09-30 0001022079 dgx:GenebasedandesoterictestingservicesMember 2021-01-01 2021-09-30 0001022079 dgx:AnatomicpathologytestingservicesMember 2022-07-01 2022-09-30 0001022079 dgx:AnatomicpathologytestingservicesMember 2021-07-01 2021-09-30 0001022079 dgx:AnatomicpathologytestingservicesMember 2022-01-01 2022-09-30 0001022079 dgx:AnatomicpathologytestingservicesMember 2021-01-01 2021-09-30 0001022079 dgx:AllotherservicesMember 2022-07-01 2022-09-30 0001022079 dgx:AllotherservicesMember 2021-07-01 2021-09-30 0001022079 dgx:AllotherservicesMember 2022-01-01 2022-09-30 0001022079 dgx:AllotherservicesMember 2021-01-01 2021-09-30 0001022079 srt:MinimumMember dgx:DiagnosticInformationServicesBusinessMember 2021-07-01 2021-09-30 0001022079 srt:MinimumMember dgx:DiagnosticInformationServicesBusinessMember 2022-07-01 2022-09-30 0001022079 dgx:FeeforserviceMember dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2022-07-01 2022-09-30 0001022079 dgx:FeeforserviceMember dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2021-07-01 2021-09-30 0001022079 dgx:FeeforserviceMember dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2022-01-01 2022-09-30 0001022079 dgx:FeeforserviceMember dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2021-01-01 2021-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:CapitatedMember dgx:HealthcareInsurersMember 2022-07-01 2022-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:CapitatedMember dgx:HealthcareInsurersMember 2021-07-01 2021-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:CapitatedMember dgx:HealthcareInsurersMember 2022-01-01 2022-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:CapitatedMember dgx:HealthcareInsurersMember 2021-01-01 2021-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2022-07-01 2022-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2021-07-01 2021-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2022-01-01 2022-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2021-01-01 2021-09-30 0001022079 dgx:GovernmentPayersMember dgx:DiagnosticInformationServicesBusinessMember 2022-07-01 2022-09-30 0001022079 dgx:GovernmentPayersMember dgx:DiagnosticInformationServicesBusinessMember 2021-07-01 2021-09-30 0001022079 dgx:GovernmentPayersMember dgx:DiagnosticInformationServicesBusinessMember 2022-01-01 2022-09-30 0001022079 dgx:GovernmentPayersMember dgx:DiagnosticInformationServicesBusinessMember 2021-01-01 2021-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2022-07-01 2022-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2021-07-01 2021-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2022-01-01 2022-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2021-01-01 2021-09-30 0001022079 dgx:PatientsMember dgx:DiagnosticInformationServicesBusinessMember 2022-07-01 2022-09-30 0001022079 dgx:PatientsMember dgx:DiagnosticInformationServicesBusinessMember 2021-07-01 2021-09-30 0001022079 dgx:PatientsMember dgx:DiagnosticInformationServicesBusinessMember 2022-01-01 2022-09-30 0001022079 dgx:PatientsMember dgx:DiagnosticInformationServicesBusinessMember 2021-01-01 2021-09-30 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2022-07-01 2022-09-30 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2021-07-01 2021-09-30 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2022-01-01 2022-09-30 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2021-01-01 2021-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2022-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2021-12-31 0001022079 dgx:GovernmentPayersMember dgx:DiagnosticInformationServicesBusinessMember 2022-09-30 0001022079 dgx:GovernmentPayersMember dgx:DiagnosticInformationServicesBusinessMember 2021-12-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2022-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2021-12-31 0001022079 dgx:PatientsMember dgx:DiagnosticInformationServicesBusinessMember 2022-09-30 0001022079 dgx:PatientsMember dgx:DiagnosticInformationServicesBusinessMember 2021-12-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2022-09-30 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2021-12-31 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2022-09-30 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2021-12-31 0001022079 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember dgx:Q2SolutionsMember 2021-01-01 2021-09-30 0001022079 us-gaap:SecuredDebtMember 2021-10-31 0001022079 us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-21 0001022079 us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2022-10-21 0001022079 us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember dgx:LoanCommitmentMember 2022-10-21 0001022079 us-gaap:LetterOfCreditMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2022-10-21 0001022079 dgx:CommercialPaperAndTermSecuredOvernightFinancingRateMember srt:MinimumMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-21 0001022079 dgx:CommercialPaperAndTermSecuredOvernightFinancingRateMember us-gaap:SecuredDebtMember srt:MaximumMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-21
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q

(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022

Or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission file number 001-12215

Quest Diagnostics Inc orporated
Delaware 16-1387862
(State of Incorporation) (I.R.S. Employer Identification Number)
500 Plaza Drive
Secaucus, NJ 07094
(973) 520-2700
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 Par Value DGX New York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☒ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of October 14, 2022, there were outstanding 113,887,466 shares of the registrant’s common stock, $.01 par value.

Table of Contents

PART I - FINANCIAL INFORMATION
Page
Item 1. Financial Statements (unaudited)
Index to unaudited consolidated financial statements filed as part of this report:

1
Table of Contents

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021
(unaudited)
(in millions, except per share data)

Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Net revenues $ 2,486 $ 2,774 $ 7,550 $ 8,044
Operating costs and expenses and other operating income:
Cost of services 1,618 1,670 4,875 4,861
Selling, general and administrative 464 427 1,311 1,263
Amortization of intangible assets 27 25 81 77
Other operating income, net ( 15 ) — ( 10 ) ( 2 )
Total operating costs and expenses, net 2,094 2,122 6,257 6,199
Operating income 392 652 1,293 1,845
Other income (expense):
Interest expense, net ( 33 ) ( 38 ) ( 106 ) ( 114 )
Other (expense) income, net ( 8 ) 40 ( 61 ) 366
Total non-operating (expense) income, net ( 41 ) 2 ( 167 ) 252
Income before income taxes and equity in earnings of equity method investees 351 654 1,126 2,097
Income tax expense ( 81 ) ( 153 ) ( 268 ) ( 483 )
Equity in earnings of equity method investees, net of taxes 6 26 41 53
Net income 276 527 899 1,667
Less: Net income attributable to noncontrolling interests 20 22 54 62
Net income attributable to Quest Diagnostics $ 256 $ 505 $ 845 $ 1,605
Earnings per share attributable to Quest Diagnostics’ common stockholders:
Basic $ 2.20 $ 4.11 $ 7.17 $ 12.63
Diluted $ 2.17 $ 4.02 $ 7.05 $ 12.41
Weighted average common shares outstanding:
Basic 116 123 117 127
Diluted 118 125 119 129









The accompanying notes are an integral part of these statements.

2
Table of Contents

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021
(unaudited)
(in millions)
Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Net income $ 276 $ 527 $ 899 $ 1,667
Other comprehensive income (loss):
Foreign currency translation adjustment ( 8 ) ( 4 ) ( 17 ) 14
Net change in available-for-sale debt securities, net of taxes — — — ( 7 )
Net deferred gain on cash flow hedges, net of taxes — 1 — 1
Other comprehensive (loss) income ( 8 ) ( 3 ) ( 17 ) 8
Comprehensive income 268 524 882 1,675
Less: Comprehensive income attributable to noncontrolling interests 20 22 54 62
Comprehensive income attributable to Quest Diagnostics $ 248 $ 502 $ 828 $ 1,613




















The accompanying notes are an integral part of these statements.

3
Table of Contents

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, 2022 AND DECEMBER 31, 2021
(unaudited)
(in millions, except per share data)
September 30,
2022 		December 31,
2021
Assets
Current assets:
Cash and cash equivalents $ 700 $ 872
Accounts receivable, net of allowance for credit losses of $ 29 and $ 31 as of September 30, 2022 and December 31, 2021, respectively
1,280 1,438
Inventories 183 208
Prepaid expenses and other current assets 171 223
Total current assets 2,334 2,741
Property, plant and equipment, net 1,707 1,707
Operating lease right-of-use assets 607 597
Goodwill 7,190 7,095
Intangible assets, net 1,115 1,167
Investments in equity method investees 138 141
Other assets 132 163
Total assets $ 13,223 $ 13,611
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses $ 1,447 $ 1,600
Current portion of long-term debt 2 2
Current portion of long-term operating lease liabilities 153 151
Total current liabilities 1,602 1,753
Long-term debt 3,980 4,010
Long-term operating lease liabilities 505 494
Other liabilities 787 792
Commitments and contingencies
Redeemable noncontrolling interest 77 79
Stockholders’ equity:
Quest Diagnostics stockholders’ equity:
Common stock, par value $ 0.01 per share; 600 shares authorized as of both September 30, 2022 and December 31, 2021; 162 shares issued as of both September 30, 2022 and December 31, 2021
2 2
Additional paid-in capital 2,272 2,260
Retained earnings 8,263 7,649
Accumulated other comprehensive loss ( 31 ) ( 14 )
Treasury stock, at cost; 48 and 43 shares as of September 30, 2022 and December 31, 2021, respectively
( 4,271 ) ( 3,453 )
Total Quest Diagnostics stockholders’ equity 6,235 6,444
Noncontrolling interests 37 39
Total stockholders’ equity 6,272 6,483
Total liabilities and stockholders’ equity $ 13,223 $ 13,611


The accompanying notes are an integral part of these statements.

4
Table of Contents

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021
(unaudited)
(in millions)
Nine Months Ended September 30,
2022 2021
Cash flows from operating activities:
Net income $ 899 $ 1,667
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 321 302
Provision for credit losses 1 3
Deferred income tax provision (benefit) 45 ( 87 )
Stock-based compensation expense 55 60
Gain on disposition of joint venture — ( 314 )
Other, net 37 ( 48 )
Changes in operating assets and liabilities:
Accounts receivable 162 45
Accounts payable and accrued expenses ( 169 ) 36
Income taxes payable ( 1 ) 49
Other assets and liabilities, net 34 39
Net cash provided by operating activities 1,384 1,752
Cash flows from investing activities:
Business acquisitions, net of cash acquired ( 106 ) ( 251 )
Capital expenditures ( 257 ) ( 259 )
Proceeds from disposition of joint venture — 755
(Increase) decrease in investments and other assets ( 6 ) 3
Net cash (used in) provided by investing activities ( 369 ) 248
Cash flows from financing activities:
Repayments of debt ( 1 ) ( 2 )
Purchases of treasury stock ( 947 ) ( 1,910 )
Exercise of stock options 96 108
Employee payroll tax withholdings on stock issued under stock-based compensation plans ( 28 ) ( 22 )
Dividends paid ( 230 ) ( 232 )
Distributions to noncontrolling interest partners ( 58 ) ( 75 )
Other financing activities, net ( 19 ) ( 38 )
Net cash used in financing activities ( 1,187 ) ( 2,171 )
Net change in cash and cash equivalents and restricted cash ( 172 ) ( 171 )
Cash and cash equivalents and restricted cash, beginning of period 872 1,158
Cash and cash equivalents and restricted cash, end of period $ 700 $ 987








The accompanying notes are an integral part of these statements.

5
Table of Contents

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021
(unaudited)
(in millions)

For the Three Months Ended September 30, 2022 Quest Diagnostics Stockholders’ Equity
Shares of
Common Stock
Outstanding 		Common
Stock 		Additional
Paid-In
Capital 		Retained
Earnings 		Accumulated
Other
Compre-
hensive Loss 		Treasury
Stock, at
Cost 		Non-
controlling
Interests 		Total
Stock-
holders’
Equity 		Redeemable Non-controlling Interest
Balance, June 30, 2022 117 $ 2 $ 2,250 $ 8,083 $ ( 23 ) $ ( 3,901 ) $ 39 $ 6,450 $ 77
Net income 256 19 275 1
Other comprehensive loss, net of taxes ( 8 ) ( 8 )
Dividends declared ( 76 ) ( 76 )
Distributions to noncontrolling interest partners ( 21 ) ( 21 ) ( 1 )
Issuance of common stock under benefit plans 2 5 7
Stock-based compensation expense 18 18
Exercise of stock options 2 26 28
Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans ( 1 ) ( 1 )
Purchases of treasury stock ( 3 ) ( 400 ) ( 400 )
Balance, September 30, 2022 114 $ 2 $ 2,272 $ 8,263 $ ( 31 ) $ ( 4,271 ) $ 37 $ 6,272 $ 77
For the Nine Months Ended September 30, 2022 Quest Diagnostics Stockholders’ Equity
Shares of
Common Stock
Outstanding 		Common
Stock 		Additional
Paid-In
Capital 		Retained
Earnings 		Accumulated
Other
Compre-
hensive Loss 		Treasury
Stock, at
Cost 		Non-
controlling
Interests 		Total
Stock-
holders’
Equity 		Redeemable Non-controlling Interest
Balance, December 31, 2021 119 $ 2 $ 2,260 $ 7,649 $ ( 14 ) $ ( 3,453 ) $ 39 $ 6,483 $ 79
Net income 845 49 894 5
Other comprehensive loss, net of taxes ( 17 ) ( 17 )
Dividends declared ( 231 ) ( 231 )
Distributions to noncontrolling interest partners ( 51 ) ( 51 ) ( 7 )
Issuance of common stock under benefit plans 1 ( 38 ) 59 21
Stock-based compensation expense 55 55
Exercise of stock options 1 5 91 96
Shares to cover employee payroll tax withholdings on stock
issued under stock-based compensation plans
( 10 ) ( 18 ) ( 28 )
Purchases of treasury stock ( 7 ) ( 950 ) ( 950 )
Balance, September 30, 2022 114 $ 2 $ 2,272 $ 8,263 $ ( 31 ) $ ( 4,271 ) $ 37 $ 6,272 $ 77





The accompanying notes are an integral part of these statements.

6
Table of Contents



QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021
(unaudited)
(in millions)
For the Three Months Ended September 30, 2021 Quest Diagnostics Stockholders’ Equity
Shares of
Common Stock
Outstanding 		Common
Stock 		Additional
Paid-In
Capital 		Retained
Earnings 		Accumulated
Other
Compre-
hensive Loss 		Treasury
Stock, at
Cost 		Non-
controlling
Interests 		Total
Stock-
holders’
Equity 		Redeemable Non-controlling Interest
Balance, June 30, 2021 122 $ 2 $ 2,555 $ 10,246 $ ( 10 ) $ ( 6,894 ) $ 41 $ 5,940 $ 78
Net income 505 19 524 3
Other comprehensive loss, net of taxes ( 3 ) ( 3 )
Dividends declared ( 76 ) ( 76 )
Distributions to noncontrolling interest partners
( 20 ) ( 20 ) ( 2 )
Issuance of common stock under benefit plans
2 4 6
Stock-based compensation expense
21 21
Exercise of stock options 1 7 33 40
Retirement of treasury stock ( 649 ) ( 3,342 ) 3,991 —
Balance, September 30, 2021 123 $ 2 $ 1,936 $ 7,333 $ ( 13 ) $ ( 2,866 ) $ 40 $ 6,432 $ 79
For the Nine Months Ended September 30, 2021 Quest Diagnostics Stockholders’ Equity
Shares of
Common Stock
Outstanding 		Common
Stock 		Additional
Paid-In
Capital 		Retained
Earnings 		Accumulated
Other
Compre-
hensive Loss 		Treasury
Stock, at
Cost 		Non-
controlling
Interests 		Total
Stock-
holders’
Equity 		Redeemable Non-controlling Interest
Balance, December 31, 2020 133 $ 2 $ 2,841 $ 9,303 $ ( 21 ) $ ( 5,366 ) $ 50 $ 6,809 $ 82
Net income 1,605 53 1,658 9
Other comprehensive income, net of taxes 8 8
Dividends declared ( 233 ) ( 233 )
Distributions to noncontrolling interest partners
( 63 ) ( 63 ) ( 12 )
Issuance of common stock under benefit plans
( 25 ) 42 17
Stock-based compensation expense
60 60
Exercise of stock options 2 19 89 108
Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans
( 10 ) ( 12 ) ( 22 )
Purchases of treasury stock
( 12 ) ( 300 ) ( 1,610 ) ( 1,910 )
Retirement of treasury stock ( 649 ) ( 3,342 ) 3,991 —
Balance, September 30, 2021 123 $ 2 $ 1,936 $ 7,333 $ ( 13 ) $ ( 2,866 ) $ 40 $ 6,432 $ 79
The accompanying notes are an integral part of these statements.

7
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(in millions, unless otherwise indicated)

1. DESCRIPTION OF BUSINESS
Background
Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") empower people to take action to improve health outcomes.  The Company uses its extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.  The Company's diagnostic information services business ("DIS") provides information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The Company provides services to a broad range of customers, including patients, clinicians, hospitals, independent delivery networks ("IDNs"), health plans, employers, and accountable care organizations ("ACOs"). The Company offers the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, patient service centers and phlebotomists in physician offices and the Company's connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals. The Company is the world's leading provider of diagnostic information services. The Company provides interpretive consultation with one of the largest medical and scientific staffs in the industry. The Company's Diagnostic Solutions businesses ("DS") are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation
The interim unaudited consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and stockholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. These interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s 2021 Annual Report on Form 10-K. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2021 but does not include all the disclosures required by accounting principles generally accepted in the United States (“GAAP”).

The accounting policies of the Company are the same as those set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2021 Annual Report on Form 10-K.

The Company's testing volume and revenues have been materially impacted by the COVID-19 pandemic, including periods of significant demand for COVID-19 testing. As a result, operating results for the three and nine months ended September 30, 2022 may not be indicative of the results that may be expected for the full year.

Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Earnings Per Share

The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method. Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding. Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially

8
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan and outstanding stock options granted under its Amended and Restated Non-Employee Director Long-Term Incentive Plan, as well as the dilutive effect of accelerated share repurchase agreements, if applicable. Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.

New Accounting Standards to be Adopted

In March 2020, the Financial Accounting Standards Board issued a new accounting standard which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform due to the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The pronouncement is effective immediately and can be applied to contract modifications through December 31, 2022. To the extent that, prior to December 31, 2022, the Company enters into any contract modifications for which the optional expedients are applied, the adoption of this standard is not expected to have a material impact on the Company’s consolidated results of operations, financial position or cash flows.

3. EARNINGS PER SHARE

The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):
Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Amounts attributable to Quest Diagnostics’ common stockholders:
Net income attributable to Quest Diagnostics $ 256 $ 505 $ 845 $ 1,605
Less: Earnings allocated to participating securities 2 2 4 6
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted
$ 254 $ 503 $ 841 $ 1,599
Weighted average common shares outstanding – basic 116 123 117 127
Effect of dilutive securities:
Stock options and performance share units 2 2 2 2
Weighted average common shares outstanding – diluted 118 125 119 129
Earnings per share attributable to Quest Diagnostics’ common stockholders:
Basic $ 2.20 $ 4.11 $ 7.17 $ 12.63
Diluted $ 2.17 $ 4.02 $ 7.05 $ 12.41
The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:
Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Stock options and performance share units 1 — — —

9
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)




The sum of basic and diluted earnings per share attributable to Quest Diagnostics' common stockholders for the first three quarters of 2021 did not equal the total for the nine months ended September 30, 2021 due to both quarterly fluctuations in the Company's earnings and in the weighted average common shares outstanding throughout the period as a result of the impact of share repurchases (see Note 9 for further details regarding the Company's share repurchases).

4. BUSINESS ACQUISITIONS

On February 1, 2022, the Company acquired Pack Health, LLC ("Pack Health"), a patient engagement company that helps individuals adopt healthier behaviors to improve outcomes, in an all cash transaction for $ 123 million, net of $ 4 million cash acquired, which consisted of cash consideration of $ 105 million and contingent consideration initially estimated at $ 18 million. The contingent consideration arrangement is dependent upon the achievement of certain revenue benchmarks. Based on the preliminary purchase price allocation, which may be revised as additional information becomes available during the measurement period, the assets acquired and liabilities assumed consist of $ 96 million of goodwill (of which $ 78 million is tax-deductible), $ 30 million of intangible assets, $ 5 million of operating lease right-of-use assets, $ 5 million of operating lease liabilities and $( 3 ) million of working capital. The intangible assets consist primarily of customer-related assets which are being amortized over a useful life of 15 years. For further details regarding the fair value of the contingent consideration, see Note 6.

The acquisition was accounted for under the acquisition method of accounting. As such, the assets acquired and liabilities assumed were recorded based on their estimated fair values as of the closing date. Supplemental pro forma combined financial information has not been presented as the impact of the acquisition is not material to the Company's consolidated financial statements. The goodwill recorded primarily includes the expected synergies resulting from combining the operations of the acquired entity with those of the Company and the value associated with an assembled workforce and other intangible assets that do not qualify for separate recognition. All of the goodwill acquired in connection with the acquisition has been allocated to the Company's DIS business. For further details regarding business segment information, see Note 12.

On December 13, 2021, the Company completed the acquisition of assets of Labtech Diagnostics, LLC ("Labtech"), an independent clinical diagnostic laboratory provider serving physicians and patients primarily in South Carolina, North Carolina, Florida and Georgia, and recorded the assets acquired and liabilities assumed based on a preliminary purchase price allocation. During the nine months ended September 30, 2022, the Company revised its purchase price allocation and recorded an $ 8 million increase to goodwill, a $ 3 million increase to customer-related intangible assets, a $ 1 million decrease to inventories and a $ 10 million increase to the estimated contingent consideration accrual. These adjustments did not have a material impact on the Company's consolidated results of operations. For further details regarding the fair value of the contingent consideration, see Note 6.

For details regarding the Company's 2021 acquisitions, see Note 5 to the audited consolidated financial statements in the Company's 2021 Annual Report on Form 10-K.

5. DISPOSITION

On April 1, 2021, the Company sold its 40 % ownership interest in Q 2 Solutions ® ("Q 2 Solutions"), its clinical trials central laboratory services joint venture, to IQVIA Holdings, Inc., its joint venture partner, for $ 760 million in an all-cash transaction. Prior to the transaction, the Company accounted for its minority interest as an equity method investment. As a result of the transaction, during the nine months ended September 30, 2021, the Company recorded a $ 314 million pre-tax gain in other (expense) income, net in the consolidated statement of operations based on the difference between the net sales proceeds and the carrying value of the investment, including $ 20 million of cumulative translation losses which were previously recorded in accumulated other comprehensive loss. During the nine months ended September 30, 2021, the Company also recorded $ 55 million of income tax expense related to the gain, consisting of $ 127 million of current income tax expense, partially offset by $ 72 million of deferred income tax benefit.


10
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


6. FAIR VALUE MEASUREMENTS

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:
Basis of Fair Value Measurements
Quoted Prices in Active Markets for Identical Assets/Liabilities Significant Other Observable Inputs Significant Unobservable Inputs
September 30, 2022 Total Level 1 Level 2 Level 3
Assets:
Deferred compensation trading securities $ 63 $ 63 $ — $ —
Cash surrender value of life insurance policies 43 — 43 —
Equity investments 14 14 — —
Total $ 120 $ 77 $ 43 $ —
Liabilities:
Deferred compensation liabilities $ 113 $ — $ 113 $ —
Contingent consideration 17 — — 17
Total $ 130 $ — $ 113 $ 17
Redeemable noncontrolling interest $ 77 $ — $ — $ 77
Basis of Fair Value Measurements
December 31, 2021 Total Level 1 Level 2 Level 3
Assets:
Deferred compensation trading securities $ 77 $ 77 $ — $ —
Cash surrender value of life insurance policies 57 — 57 —
Equity investments 44 44 — —
Available-for-sale debt securities 1 — — 1
Total $ 179 $ 121 $ 57 $ 1
Liabilities:
Deferred compensation liabilities $ 143 $ — $ 143 $ —
Contingent consideration 5 — — 5
Total $ 148 $ — $ 143 $ 5
Redeemable noncontrolling interest $ 79 $ — $ — $ 79
A detailed description regarding the Company's fair value measurements is contained in Note 7 to the audited consolidated financial statements in the Company's 2021 Annual Report on Form 10-K.

The Company offers certain employees the opportunity to participate in a non-qualified supplemental deferred compensation plan. A participant's deferrals, together with Company matching credits, are invested in a variety of participant-directed stock and bond mutual funds that are classified as trading securities. The trading securities are classified within Level

11
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


1 of the fair value hierarchy because the changes in the fair value of these securities are measured using quoted prices in active markets based on the market price per unit multiplied by the number of units held, exclusive of any transaction costs. A corresponding adjustment for changes in fair value of the trading securities is also reflected in the changes in fair value of the deferred compensation obligation. The deferred compensation liabilities are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the trading securities.

The Company offers certain employees the opportunity to participate in a non-qualified deferred compensation program. A participant's deferrals, together with Company matching credits, are “invested” at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator. The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments. Changes in the fair value of the deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the deferred compensation obligation are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the hypothetical investments. Deferrals under the plan currently may only be made by participants who made deferrals under the plan in 2017.

The Company's investment portfolio primarily includes equity investments comprised mostly of strategic holdings in companies concentrated in the life sciences and healthcare industries. Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) with readily determinable fair values are measured at fair value in prepaid expenses and other current assets in the Company's consolidated balance sheet. Such equity investments are classified within Level 1 of the fair value hierarchy because the changes in the fair values of the securities are measured using quoted prices in active markets based on the market price per share multiplied by the number of shares held, exclusive of any transaction costs.

The Company's available-for-sale debt securities are measured at fair value using discounted cash flows. These fair value measurements are classified within Level 3 of the fair value hierarchy as the fair value is based on significant inputs that are not observable. Significant inputs include cash flows projections and a discount rate.
In connection with the acquisitions of Pack Health and Labtech, the Company has contingent consideration obligations, with a potential maximum aggregate payment of $ 40 million, that are to be paid based on the achievement of certain testing volume or revenue benchmarks. Contingent consideration accruals are measured at fair value using either an option-pricing method or a Monte Carlo method and are classified within Level 3 of the fair value hierarchy as the fair value is determined based on significant inputs that are not observable. Significant inputs include management’s estimate of volume or revenue and other market inputs, including comparable company revenue volatility ( 7.5 %) and a discount rate (ranging from 2.5 % to 3.0 %).

For further details regarding the Company's acquisitions, see Note 5 to the audited consolidated financial statements in the Company's 2021 Annual Report on Form 10-K and Note 4.

The following table provides a reconciliation of the beginning and ending balances of liabilities using significant unobservable inputs (Level 3):
Contingent Consideration
Balance, December 31, 2021 $ 5
Purchases, additions and issuances 28
Settlements ( 15 )
Total fair value adjustments included in earnings - realized/unrealized ( 1 )
Balance, September 30, 2022 $ 17

The $ 1 million net gain included in earnings associated with the change in the fair value of contingent consideration for the nine months ended September 30, 2022 is reported in other operating income, net.


12
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


In connection with the sale of an 18.9 % noncontrolling interest in a subsidiary to UMass Memorial Medical Center ("UMass") on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. As of September 30, 2022, the redeemable noncontrolling interest was presented at its fair value. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy because the fair value is based on a discounted cash flow analysis that takes into account, among other items, the joint venture's expected future cash flows, long term growth rates, and a discount rate commensurate with economic risk.
The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments. As of September 30, 2022 and December 31, 2021, the fair value of the Company’s debt was estimated at $ 3.6 billion and $ 4.4 billion, respectively. Principally all of the Company's debt is classified within Level 1 of the fair value hierarchy because the fair value of the debt is estimated based on rates currently offered to the Company with identical terms and maturities, using quoted active market prices and yields, taking into account the underlying terms of the debt instruments.

7. GOODWILL AND INTANGIBLE ASSETS

The changes in goodwill for the nine months ended September 30, 2022 and for the year ended December 31, 2021 were as follows:
September 30, 2022 December 31, 2021
Balance, beginning of period $ 7,095 $ 6,873
Goodwill acquired during the period 97 228
Adjustments to goodwill ( 2 ) ( 6 )
Balance, end of period $ 7,190 $ 7,095
Principally all of the Company’s goodwill as of September 30, 2022 and December 31, 2021 was associated with its DIS business.

For the nine months ended September 30, 2022, goodwill acquired was principally associated with the acquisition of Pack Health, and adjustments to goodwill primarily related to foreign currency translation, largely offset by an adjustment of the purchase price allocation for Labtech (see Note 4). For the year ended December 31, 2021, goodwill acquired was principally associated with the acquisitions of the assets of the outreach laboratory services business of Mercy Health and the assets of Labtech (see Note 5 to the audited consolidated financial statements in the Company's 2021 Annual Report on Form 10-K), and adjustments to goodwill related to foreign currency translation.


13
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


Intangible assets as of September 30, 2022 and December 31, 2021 consisted of the following:
Weighted
Average
Amortization
Period
(in years) 		September 30, 2022 December 31, 2021
Cost Accumulated
Amortization 		Net Cost Accumulated
Amortization 		Net
Amortizing intangible assets:
Customer-related 17 $ 1,608 $ ( 796 ) $ 812 $ 1,581 $ ( 726 ) $ 855
Non-compete agreements 9 3 ( 3 ) — 3 ( 2 ) 1
Technology 15 137 ( 80 ) 57 141 ( 74 ) 67
Other 6 114 ( 104 ) 10 109 ( 101 ) 8
Total 17 1,862 ( 983 ) 879 1,834 ( 903 ) 931
Intangible assets not subject to amortization:
Trade names 235 — 235 235 — 235
Other 1 — 1 1 — 1
Total intangible assets $ 2,098 $ ( 983 ) $ 1,115 $ 2,070 $ ( 903 ) $ 1,167
The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of September 30, 2022 is as follows:

Year Ending December 31,
Remainder of 2022 $ 27
2023 105
2024 102
2025 100
2026 95
2027 84
Thereafter 366
Total $ 879

8. FINANCIAL INSTRUMENTS

The Company uses derivative financial instruments, from time to time, to manage its exposure to market risks for changes in interest rates and foreign currencies. This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. These policies prohibit holding or issuing derivative financial instruments for speculative purposes. The Company does not enter into derivative financial instruments that contain credit-risk-related contingent features or requirements to post collateral.

Interest Rate Risk
The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company's debt obligations consist of fixed-rate and, from time to time, variable-rate debt instruments. The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has historically entered into interest rate swap agreements.


14
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


Interest rate swaps involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements between the counterparties are recognized as an adjustment to interest expense, net.

Interest Rate Derivatives – Cash Flow Hedges

From time to time, the Company has entered into various interest rate lock agreements and forward-starting interest rate swap agreements to hedge part of the Company's interest rate exposure associated with the variability in future cash flows attributable to changes in interest rates.

Interest Rate Derivatives – Fair Value Hedges

Historically, the Company has entered into various fixed-to-variable interest rate swap agreements in order to convert a portion of the Company's long-term debt into variable interest rate debt. All such fixed-to-variable interest rate swap agreements have been terminated and proceeds from the terminations have been reflected as basis adjustments to the hedged debt instruments and are being amortized as a reduction of interest expense, net over the remaining terms of such debt instruments.

As of September 30, 2022 and December 31, 2021, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:
Hedge Accounting Basis Adjustment (a)
Balance Sheet Classification September 30, 2022 December 31, 2021
Long-term debt $ 29 $ 38

(a) As of both September 30, 2022 and December 31, 2021, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships.

A detailed description regarding the Company's use of derivative financial instruments is contained in Note 15 to the audited consolidated financial statements in the Company's 2021 Annual Report on Form 10-K.

9. STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST
Stockholders' Equity

Changes in Accumulated Other Comprehensive Loss by Component

Comprehensive income (loss) includes:

• Foreign currency translation adjustments;
• Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Note 8); and
• Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax on available-for-sale debt securities.

For the three and nine months ended September 30, 2022 and 2021, the tax effects related to the deferred gains (losses) on cash flow hedges and net changes in available-for-sale debt securities were not material. Foreign currency translation adjustments related to indefinite investments in non-U.S. subsidiaries are not adjusted for income taxes.

Dividend Program
During each of the first three quarters of 2022, the Company's Board of Directors declared a quarterly cash dividend of $ 0.66 per common share. During each of the four quarters of 2021, the Company's Board of Directors declared a quarterly cash dividend of $ 0.62 per common share.

15
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


Share Repurchase Program
In February 2022, the Company's Board of Directors increased the size of its share repurchase program by $ 1 billion. As of September 30, 2022, $ 746 million remained available under the Company’s share repurchase authorization. The share repurchase authorization has no set expiration or termination date.
Share Repurchases

For the nine months ended September 30, 2022, the Company repurchased 7.1 million shares of its common stock for $ 950 million.
For the nine months ended September 30, 2021, the Company repurchased 12.5 million shares of its common stock for $ 1.6 billion, including 9.1 million shares repurchased under accelerated share repurchase agreements ("ASRs") as follows.

In April 2021, the Company entered into ASRs with several financial institutions to repurchase its common stock as part of its share repurchase program. Each of the ASRs was structured to permit the Company to purchase shares immediately with the final purchase price of those shares determined by the volume-weighted average price of the Company's common stock, less a fixed discount, during the repurchase period, which ended during the fourth quarter of 2021. For the nine months ended September 30, 2021, the Company paid $ 1.5 billion to the financial institutions and initially received 9.1 million shares of its common stock for a value of $ 1.2 billion, which represented 80 % of the total value of shares to be repurchased under the ASRs based on the stock price at inception of the ASRs.

Shares Reissued from Treasury Stock

For the nine months ended September 30, 2022 and 2021, the Company reissued 1.6 million shares and 1.7 million shares, respectively, from treasury stock under its Employee Stock Purchase Plan and its stock-based compensation program. For details regarding the Company's stock ownership and compensation plans, see Note 17 to the audited consolidated financial statements in the Company's 2021 Annual Report on Form 10-K.

Treasury Stock Retirement

During the three months ended September 30, 2021, the Company retired 55 million shares of treasury stock. In accordance with the Company's policy, the amount paid to repurchase the shares in excess of par value was allocated between retained earnings and additional paid-in capital based on a pro-rata allocation of additional paid-in capital at the time of the share retirement.
Redeemable Noncontrolling Interest

In connection with the sale of an 18.9 % noncontrolling interest in a subsidiary to UMass on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. The subsidiary performs diagnostic information services in a defined territory within the state of Massachusetts. Since the redemption of the noncontrolling interest is outside of the Company's control, it has been presented outside of stockholders' equity at the greater of its carrying amount or its fair value. As of September 30, 2022 and December 31, 2021, the redeemable noncontrolling interest was presented at its fair value. For further details regarding the fair value of the redeemable noncontrolling interest, see Note 6.


16
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)



10. SUPPLEMENTAL CASH FLOW AND OTHER DATA

Supplemental cash flow and other data for the three and nine months ended September 30, 2022 and 2021 was as follows:
Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Depreciation expense $ 81 $ 76 $ 240 $ 225
Amortization expense 27 25 81 77
Depreciation and amortization expense $ 108 $ 101 $ 321 $ 302
Interest expense $ ( 37 ) $ ( 38 ) $ ( 112 ) $ ( 114 )
Interest income 4 — 6 —
Interest expense, net $ ( 33 ) $ ( 38 ) $ ( 106 ) $ ( 114 )
Interest paid $ 32 $ 33 $ 110 $ 111
Income taxes paid $ 5 $ 187 $ 187 $ 522
Accounts payable associated with capital expenditures $ 30 $ 24 $ 30 $ 24
Accounts payable associated with purchases of treasury stock $ 26 $ — $ 26 $ —
Dividends payable $ 75 $ 77 $ 75 $ 77
Businesses acquired:
Fair value of assets acquired $ — $ 20 $ 143 $ 254
Fair value of liabilities assumed — — 15 3
Fair value of net assets acquired — 20 128 251
Merger consideration payable — — ( 18 ) —
Cash paid for business acquisitions — 20 110 251
Less: Cash acquired — — 4 —
Business acquisitions, net of cash acquired $ — $ 20 $ 106 $ 251
Leases:
Leased assets obtained in exchange for new operating lease liabilities $ 49 $ 46 $ 133 $ 115
During the nine months ended September 30, 2022, the Company amended a real estate lease and, based on the updated terms, the classification of the lease changed from a finance lease to an operating lease. As a result, the Company recorded a $ 31 million operating lease right-of-use asset.

17
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


11. COMMITMENTS AND CONTINGENCIES

Letters of Credit

The Company can issue letters of credit totaling $ 100 million under its $ 600 million secured receivables credit facility and $ 150 million under its $ 750 million senior unsecured revolving credit facility. For further discussion regarding the Company's secured receivables credit facility and senior unsecured revolving credit facility, see Note 13 to the audited consolidated financial statements in the Company's 2021 Annual Report on Form 10-K and Note 15.
In support of its risk management program, $ 70 million in letters of credit under the secured receivables credit facility were outstanding as of September 30, 2022, providing collateral for current and future automobile liability and workers’ compensation loss payments.

Contingent Lease Obligations
The Company remains subject to contingent obligations under certain real estate leases for which no liability has been recorded. For further details, see Note 18 to the audited consolidated financial statements in the Company’s 2021 Annual Report on Form 10-K.

Certain Legal Matters

The Company may incur losses associated with these proceedings and investigations, but it is not possible to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to the certification of a class or classes and the size of any certified class, if applicable, and/or the lack of resolution of significant factual and legal issues. The Company has insurance coverage rights in place (limited in amount; subject to deductible) for certain potential costs and liabilities related to these proceedings and investigations.

401(k) Plan Lawsuit
In 2020, two putative class action lawsuits were filed in the U.S. District Court for New Jersey against the Company and other defendants with respect to the Company’s 401(k) plan. The complaint alleges, among other things, that the fiduciaries of the 401(k) plan breached their duties by failing to disclose the expenses and risks of plan investment options, allowing unreasonable administration expenses to be charged to plan participants, and selecting and retaining high cost and poor performing investments. In October 2020, the court consolidated the two lawsuits under the caption In re: Quest Diagnostics ERISA Litigation and plaintiffs filed a consolidated amended complaint. In May 2021, the court denied the Company's motion to dismiss the complaint.

AMCA Data Security Incident

On June 3, 2019, the Company reported that Retrieval-Masters Creditors Bureau, Inc./American Medical Collection Agency (“AMCA”) had informed the Company and Optum360 LLC that an unauthorized user had access to AMCA’s system between August 1, 2018 and March 30, 2019 (the “AMCA Data Security Incident”). Optum360 provides revenue management services to the Company, and AMCA provided debt collection services to Optum360. AMCA first informed the Company of the AMCA Data Security Incident on May 14, 2019. AMCA’s affected system included financial information (e.g., credit card numbers and bank account information), medical information and other personal information (e.g., social security numbers). Test results were not included. Neither Optum360’s nor the Company’s systems or databases were involved in the incident. AMCA also informed the Company that information pertaining to other laboratories’ customers was also affected. Following announcement of the AMCA Data Security Incident, AMCA sought protection under the U.S. bankruptcy laws. The bankruptcy proceeding has been dismissed.


18
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


Numerous putative class action lawsuits were filed against the Company related to the AMCA Data Security Incident. The U.S. Judicial Panel on Multidistrict Litigation transferred the cases that were then still pending to, and consolidated them for pre-trial proceedings in, the U.S. District Court for New Jersey. In November 2019, the plaintiffs in the multidistrict proceeding filed a consolidated putative class action complaint against the Company and Optum360 that named additional individuals as plaintiffs and that asserted a variety of common law and statutory claims in connection with the AMCA Data Security Incident. In January 2020, the Company moved to dismiss the consolidated complaint; the motion to dismiss was granted in part and denied in part. Discovery is proceeding.

In addition, the Company has been notified that numerous state attorney general offices were investigating or otherwise seeking information and/or documents, and that certain U.S. senators were seeking information, from the Company related to the AMCA Data Security Incident.

ReproSource Fertility Diagnostics, Inc.

ReproSource Fertility Diagnostics, Inc. (“ReproSource”), a subsidiary of the Company, is subject to two putative class action lawsuits in the U.S. District Court for Massachusetts: Bickham v. ReproSource Fertility Diagnostics, Inc. and Gordon v. ReproSource Fertility Diagnostics, Inc. The class actions are related to a data security incident that occurred in August 2021 in which an unauthorized party may have accessed or acquired protected health information and personally identifiable information of ReproSource patients. The complaints generally allege that ReproSource, among other claims, failed to adequately safeguard customers’ private information. ReproSource has moved to dismiss both complaints. In addition, the Company had been notified that the Office of Civil Rights of the U.S. Department of Health and Human Services (“OCR”) and three state governmental authorities were investigating or otherwise seeking information and/or documents related to the incident. The OCR and one state investigation have been closed, and the other state investigations are inactive.

Other Legal Matters

In the normal course of business, the Company has been named, from time to time, as a defendant in various legal actions, including arbitrations, class actions and other litigation, arising in connection with the Company's activities as a provider of diagnostic testing, information and services. These actions could involve claims for substantial compensatory and/or punitive damages or claims for indeterminate amounts of damages, and could have an adverse impact on the Company's client base and reputation.

The Company is also involved, from time to time, in other reviews, investigations and proceedings by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief.

The federal or state governments may bring claims based on the Company's current practices, which it believes are lawful. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of government or private payers. The Company is aware of lawsuits, and from time to time has received subpoenas, related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws. The Company understands that there may be other pending qui tam claims brought by former employees or other "whistleblowers" as to which the Company cannot determine the extent of any potential liability.

Management cannot predict the outcome of such matters. Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the Company's consolidated results of operations or cash flows in the period in which the impact of such matters is determined or paid.

These matters are in different stages. Some of these matters are in their early stages. Matters may involve responding to and cooperating with various government investigations and related subpoenas. As of September 30, 2022, the Company does not believe that material losses related to legal matters are probable.


19
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


Reserves for legal matters totaled $ 5 million and $ 4 million as of September 30, 2022 and December 31, 2021, respectively.

Reserves for General and Professional Liability Claims

As a general matter, providers of clinical testing services may be subject to lawsuits alleging negligence or other similar legal claims. These suits could involve claims for substantial damages. Any professional liability litigation could also have an adverse impact on the Company's client base and reputation. The Company maintains various liability insurance coverages for, among other things, claims that could result from providing, or failing to provide, clinical testing services, including inaccurate testing results, and other exposures. The Company's insurance coverage limits its maximum exposure on individual claims; however, the Company is essentially self-insured for a significant portion of these claims.

The Company is subject to a series of individual claims brought by persons in Ireland related to allegations stemming from pap smear screening services performed by the Company. In general, claimants have alleged that the results of certain pap smear screening tests performed by the Company and other providers, pursuant to a program coordinated by the Irish government, were incorrect for individuals who were later diagnosed with cervical cancer. The Irish government and an independent scoping inquiry commissioned by the Irish government found that the Company’s performance of its screening services for the Irish cervical cancer screening program were in accordance with both Ireland’s requirements and international standards. The Company has settled claims made by certain individuals, is a party in multiple lawsuits and may be served as a party in additional lawsuits. The Company does not believe that the resolution of existing or future claims will have a material adverse effect on its financial position or liquidity, but the ultimate outcomes of these claims are unpredictable and subject to significant uncertainties.

Reserves for such matters, including those associated with both asserted and incurred but not reported claims, are established on an undiscounted basis by considering actuarially determined losses based upon the Company's historical and projected loss experience. Such reserves totaled $ 162 million and $ 159 million as of September 30, 2022 and December 31, 2021, respectively.

While the basis for claims reserves is actuarially determined losses based upon the Company's historical and projected loss experience, the process of analyzing, assessing and establishing reserve estimates relative to these types of claims involves a high degree of judgment. Although the Company believes that its present reserves and insurance coverage are sufficient to cover currently estimated exposures, it is possible that the Company may incur liabilities in excess of its recorded reserves or insurance coverage. Changes in the facts and circumstances associated with claims could have a material impact on the Company’s results of operations (principally costs of services), cash flows and financial condition in the period that reserve estimates are adjusted or paid.

12. BUSINESS SEGMENT INFORMATION

The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's chief operating decision maker ("CODM"), assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers, and ACOs. The Company is the world's leading provider of diagnostic information services, which includes providing information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The DIS business accounted for greater than 95 % of net revenues in 2022 and 2021.

All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.
As of September 30, 2022, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States.

The following table is a summary of segment information for the three and nine months ended September 30, 2022 and 2021. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating

20
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2021 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.
Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Net revenues:
DIS business $ 2,419 $ 2,703 $ 7,344 $ 7,820
All other operating segments 67 71 206 224
Total net revenues $ 2,486 $ 2,774 $ 7,550 $ 8,044
Operating earnings (loss):
DIS business $ 441 $ 713 $ 1,445 $ 2,026
All other operating segments 3 8 16 26
General corporate activities ( 52 ) ( 69 ) ( 168 ) ( 207 )
Total operating income 392 652 1,293 1,845
Non-operating (expense) income, net ( 41 ) 2 ( 167 ) 252
Income before income taxes and equity in earnings of equity method investees 351 654 1,126 2,097
Income tax expense ( 81 ) ( 153 ) ( 268 ) ( 483 )
Equity in earnings of equity method investees, net of taxes 6 26 41 53
Net income 276 527 899 1,667
Less: Net income attributable to noncontrolling interests 20 22 54 62
Net income attributable to Quest Diagnostics $ 256 $ 505 $ 845 $ 1,605

Net revenues by major service were as follows:

Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Routine clinical testing and other services $ 1,119 $ 1,210 $ 3,283 $ 3,392
COVID-19 testing services 316 709 1,270 2,048
Gene-based and esoteric (including advanced diagnostics) testing services 835 646 2,361 1,972
Anatomic pathology testing services 149 138 430 408
All other 67 71 206 224
Total net revenues $ 2,486 $ 2,774 $ 7,550 $ 8,044

13. REVENUE RECOGNITION

DIS

Net revenues in the Company’s DIS business accounted for over 95 % of the Company’s total net revenues for the three and nine months ended September 30, 2022 and 2021 and are primarily comprised of a high volume of relatively low-dollar transactions. The DIS business, which provides clinical testing services and other services, satisfies its performance obligations and recognizes revenues primarily upon completion of the testing process (when results are reported) or when

21
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


services have been rendered. The Company estimates the amount of consideration it expects to be entitled to receive from customer groups in exchange for providing services using the portfolio approach. These estimates include the impact of contractual allowances (including payer denials), and patient price concessions. The portfolios determined using the portfolio approach consist of the following groups of customers: healthcare insurers, government payers (Medicare and Medicaid programs), client payers and patients.

For further details regarding revenue recognition in the Company's DIS business, see Note 3 to the audited consolidated financial statements in the Company's 2021 Annual Report on Form 10-K.

DS

The Company’s DS businesses primarily satisfy their performance obligations and recognize revenues when delivery has occurred or services have been rendered.

Net Revenue and Net Accounts Receivable by Customer Type

The approximate percentage of net revenue by type of customer was as follows:
Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Healthcare insurers:
Fee-for-service 39 % 41 % 39 % 39 %
Capitated 3 2 3 3
Total healthcare insurers 42 43 42 42
Government payers 11 10 11 10
Client payers 33 31 33 33
Patients (including coinsurance and deductible responsibilities) 11 13 11 12
Total DIS 97 97 97 97
DS 3 3 3 3
Net revenues 100 % 100 % 100 % 100 %
The approximate percentage of net accounts receivable by type of customer was as follows:
September 30, 2022 December 31, 2021
Healthcare Insurers 28 % 32 %
Government Payers 6 6
Client Payers 43 38
Patients (including coinsurance and deductible responsibilities) 19 21
Total DIS 96 97
DS 4 3
Net accounts receivable 100 % 100 %


14. TAXES ON INCOME

For the nine months ended September 30, 2022 and 2021, the effective income tax rate was 23.8 % and 23.1 %, respectively. For the nine months ended September 30, 2021, the effective income tax rate benefited from a lower effective income tax rate, 17.6 %, on the gain on the sale of the Company's 40 % ownership interest in Q 2 Solutions (see Note 5). In

22
Table of Contents
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


addition, the effective income tax rate benefited from $ 10 million and $ 15 million of excess tax benefits associated with stock-based compensation arrangements for the nine months ended September 30, 2022 and 2021, respectively.

15. SUBSEQUENT EVENTS

During October 2022, the Company amended its $ 600 million secured receivables credit facility in order to extend the maturity dates for each underlying commitment by one year while decreasing the aggregate borrowing capacity under the secured receivables credit facility to $ 525 million. Under the amended secured receivables credit facility, the Company can borrow against a $ 425 million loan commitment, half of which matures in October 2023 and half of which matures in October 2024. Additionally, the Company can issue up to $ 100 million of letters of credit through October 2024. Borrowings under the secured receivables credit facility are collateralized by certain domestic receivables. Prior to the amendment, interest on borrowings under the secured receivables credit facility was based on either commercial paper rates for highly-rated issuers or LIBOR, plus a spread. Subsequent to the amendment, interest on borrowings under the facility will be based on either commercial paper rates for highly-rated issuers or the Term Secured Overnight Financing Rate, plus a spread of 0.725 % to 0.80 %.

23
Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Our Company

Diagnostic Information Services

Quest Diagnostics empowers people to take action to improve health outcomes. We use our extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Our diagnostic information services business ("DIS") provides information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. We provide services to a broad range of customers, including patients, clinicians, hospitals, independent delivery networks ("IDNs"), health plans, employers and accountable care organizations ("ACOs"). We offer the broadest access in the United States to diagnostic information services through our nationwide network of laboratories, patient service centers and phlebotomists in physician offices and our connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals. We are the world's leading provider of diagnostic information services. We provide interpretive consultation with one of the largest medical and scientific staffs in the industry. Our DIS business makes up greater than 95% of our consolidated net revenues.

We assess our revenue performance for the DIS business based upon, among other factors, volume (measured by test requisitions) and revenue per requisition. Each requisition accompanies patient specimens, indicating the test(s) to be performed and the party to be billed for the test(s). Revenue per requisition is impacted by various factors, including, among other items, the impact of fee schedule changes (i.e., unit price), test mix, payer mix, and the number of tests per requisition. Management uses number of requisitions and revenue per requisition data to assist with assessing the growth and performance of the business, including understanding trends affecting number of requisitions, pricing and test mix. Therefore, we believe that information related to changes in these metrics from period to period are useful information for investors as it allows them to assess the performance of the business.

Diagnostic Solutions

In our Diagnostic Solutions ("DS") businesses, which represent the balance of our consolidated net revenues, we offer a variety of solutions for life insurers and healthcare organizations and clinicians. We are the leading provider of risk assessment services for the life insurance industry. In addition, we offer healthcare organizations and clinicians robust information technology solutions.

Third Quarter Highlights
Three Months Ended September 30,
2022 2021
(dollars in millions, except per share data)
Net revenues $2,486 $2,774
Base business revenues (a) $2,170 $2,065
COVID-19 testing revenues $316 $709
DIS revenues $2,419 $2,703
Revenue per requisition change (5.1)% (5.4)%
Requisition volume change (6.2)% 5.3%
Organic requisition volume change (6.4)% 3.2%
DS revenues $67 $71
Net income attributable to Quest Diagnostics $256 $505
Diluted earnings per share $2.17 $4.02
Net cash provided by operating activities $502 $561

(a) Excludes COVID-19 testing.


24
Table of Contents
The impacts that the COVID-19 pandemic had on our DIS revenues, including requisition volume and revenue per requisition are discussed further below under "Impact of COVID-19" and "Results of Operations".

For further discussion of the year-over-year changes for the three months ended September 30, 2022 compared to the three months ended September 30, 2021, see "Results of Operations" below.

Impact of COVID - 19

As a novel strain of coronavirus (COVID-19) continues to impact the economy of the United States and other countries around the world, we are committed to being a part of the coordinated public and private sector response to this unprecedented challenge. We have made substantial investments to expand and maintain the amount of COVID-19 testing available to the country. We have been effectively managing challenges in the global supply chain; and, at this point, we have sufficient supplies to conduct our business.

Due to the COVID-19 pandemic, we have experienced significant volatility, including periods of material decline compared to prior year periods in testing volume in our base business (which excludes COVID-19 testing) and periods of significant demand for COVID-19 testing services, with demand generally fluctuating in line with changes in the prevalence of the virus and related variants. Additionally, compared to historical levels, our revenue per requisition has been positively impacted by COVID-19 molecular testing.

Acquisition of Pack Health, LLC ("Pack Health")

On February 1, 2022, we completed the acquisition of Pack Health, a patient engagement company that helps individuals adopt healthier behaviors to improve outcomes, in an all cash transaction for $123 million, net of $4 million cash acquired, which consisted of cash consideration of $105 million and contingent consideration initially estimated at $18 million. The contingent consideration arrangement is dependent upon the achievement of certain revenue benchmarks. The acquired business is included in our DIS business.

For further details, see Notes 4 and 6 to the interim unaudited consolidated financial statements.

Invigorate Program
We are engaged in a multi-year program called Invigorate, which is designed to reduce our cost structure and improve our performance. We currently aim annually to achieve savings and productivity improvements of approximately 3% of our costs, which we believe will help offset pressures from the current inflationary environment.

Invigorate has consisted of several flagship programs, with structured plans in each, to drive savings and improve performance across the customer value chain. These flagship programs include: organization excellence; information technology excellence; procurement excellence; field and customer service excellence; lab excellence; and revenue services excellence. In addition to these programs, we have identified key themes to change how we operate including reducing denials and patient price concessions; further digitizing our business; standardization and automation; and optimization initiatives in our lab network and patient service center network. We believe that our efforts to standardize our information technology systems, equipment and data also foster our efforts to strengthen our foundation for growth and support the value creation initiatives of our clinical franchises by enhancing our operational flexibility, empowering and enhancing the customer experience, facilitating the delivery of actionable insights and bolstering our large data platform.

For the nine months ended September 30, 2022, we incurred $32 million of pre-tax charges under our Invigorate program primarily consisting of systems conversion and integration costs, all of which resulted in cash expenditures. Additional restructuring charges may be incurred in future periods as we identify additional opportunities to achieve further savings and productivity improvements.

Critical Accounting Policies
There have been no significant changes to our critical accounting policies from those disclosed in our 2021 Annual Report on Form 10-K .
Impact of New Accounting Standards


25
Table of Contents
The adoption of new accounting standards, if any, is discussed in Note 2 to the interim unaudited consolidated financial statements.

The impact of recent accounting pronouncements not yet effective on our consolidated financial statements, if any, is also discussed in Note 2 to the interim unaudited consolidated financial statements.

26
Table of Contents

Results of Operations
The following tables set forth certain results of operations data for the periods presented:

Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 $ Change % Change 2022 2021 $ Change % Change
(dollars in millions, except per share amounts)
Net revenues:
DIS business $ 2,419 $ 2,703 $ (284) (10.5) % $ 7,344 $ 7,820 $ (476) (6.1) %
DS businesses 67 71 (4) (5.9) 206 224 (18) (7.9)
Total net revenues $ 2,486 $ 2,774 $ (288) (10.4) % $ 7,550 $ 8,044 $ (494) (6.1) %
Operating costs and expenses and other operating income:
Cost of services $ 1,618 $ 1,670 $ (52) (3.1) % $ 4,875 $ 4,861 $ 14 0.3 %
Selling, general and administrative 464 427 37 8.5 1,311 1,263 48 3.8
Amortization of intangible assets 27 25 2 4.3 81 77 4 3.4
Other operating income, net (15) — (15) NM (10) (2) (8) NM
Total operating costs and expenses, net $ 2,094 $ 2,122 $ (28) (1.4) % $ 6,257 $ 6,199 $ 58 0.9 %
Operating income $ 392 $ 652 $ (260) (39.7) % $ 1,293 $ 1,845 $ (552) (29.9) %
Other income (expense):
Interest expense, net $ (33) $ (38) $ 5 (12.5) % $ (106) $ (114) $ 8 (6.3) %
Other (expense) income, net (8) 40 (48) NM (61) 366 (427) NM
Total non-operating (expense) income, net $ (41) $ 2 $ (43) NM $ (167) $ 252 $ (419) NM
Income tax expense $ (81) $ (153) $ 72 (47.3) % $ (268) $ (483) $ 215 (44.6) %
Effective income tax rate
23.0 % 23.4 % 23.8 % 23.1 %
Equity in earnings of equity method investees, net of taxes $ 6 $ 26 $ (20) (80.2) % $ 41 $ 53 $ (12) (24.5) %
Net income attributable to Quest Diagnostics $ 256 $ 505 $ (249) (49.3) % $ 845 $ 1,605 $ (760) (47.4) %
Diluted earnings per common share attributable to Quest Diagnostics' common stockholders $ 2.17 $ 4.02 $ (1.85) (46.0) % $ 7.05 $ 12.41 $ (5.36) (43.2) %
NM - Not Meaningful



27
Table of Contents

The following table sets forth certain results of operations data as a percentage of net revenues for the periods presented:
Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Net revenues:
DIS business 97.3 % 97.4 % 97.3 % 97.2 %
DS businesses 2.7 2.6 2.7 2.8
Total net revenues 100.0 % 100.0 % 100.0 % 100.0 %
Operating costs and expenses and other operating income:
Cost of services 65.1 % 60.2 % 64.6 % 60.4 %
Selling, general and administrative 18.7 15.4 17.4 15.7
Amortization of intangible assets 1.1 0.9 1.1 1.0
Other operating income, net (0.7) — (0.2) —
Total operating costs and expenses, net 84.2 % 76.5 % 82.9 % 77.1 %
Operating income 15.8 % 23.5 % 17.1 % 22.9 %
Operating Results

Results for the three months ended September 30, 2022 were affected by certain items that on a net basis decreased diluted earnings per share by $0.19 as follows:

• pre-tax amortization expense of $27 million recorded in amortization of intangible assets or $0.17 per diluted share;
• pre-tax charges of $13 million ($6 million in cost of services and $7 million in selling, general and administrative expenses), or $0.08 per diluted share, primarily associated with workforce reductions, systems conversions and integration incurred in connection with further restructuring and integrating our business; and
• pre-tax charges of $2 million in other (expense) income, net or $0.01 per diluted share, representing net losses associated with changes in the carrying value of our strategic investments; partially offset by
• a net pre-tax gain of $9 million ($2 million of charges in cost of services, and $5 million of charges in selling, general and administrative expenses offset by $16 million of gains in other operating income, net), or $0.06 per diluted share, primarily representing a $10 million gain from a payroll tax credit under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") associated with the retention of employees and a $7 million gain associated with the decrease in the fair value of the contingent consideration accrual associated with previous acquisitions, partially offset by $5 million of costs associated with donations, contributions and other financial support through Quest for Health Equity (our initiative with the Quest Diagnostics Foundation to reduce health disparities in underserved communities); and
• excess tax benefits associated with stock-based compensation arrangements of $1 million, or $0.01 per diluted share, recorded in income tax expense.
Results for the nine months ended September 30, 2022 were affected by certain items that on a net basis decreased diluted earnings per share by $0.89 as follows:

• pre-tax amortization expense of $81 million recorded in amortization of intangible assets or $0.50 per diluted share;
• pre-tax charges of $39 million ($30 million in other (expense) income, net and $9 million in equity in earnings of equity method investees, net of taxes), or $0.24 per diluted share, representing net losses associated with changes in the carrying value of our strategic investments;
• pre-tax charges of $37 million ($13 million in cost of services and $24 million in selling, general and administrative expenses), or $0.23 per diluted share, primarily associated with workforce reductions, systems conversions and integration incurred in connection with further restructuring and integrating our business; and

28
Table of Contents
• net pre-tax charges of $1 million ($2 million of charges in cost of services, and $9 million of charges in selling, general and administrative expenses largely offset by $10 million of gains in other operating income, net), or $0.00 per diluted share, primarily representing $9 million of costs associated with donations, contributions and other financial support through Quest for Health Equity offset by a $10 million gain from a payroll tax credit under the CARES Act associated with the retention of employees; partially offset by
• excess tax benefits associated with stock-based compensation arrangements of $10 million, or $0.08 per diluted share, recorded in income tax expense.

For the three and nine months ended September 30, 2022, diluted earnings per share benefited from the impact of share repurchases, including under accelerated share repurchase agreements ("ASRs") entered into in April 2021 to repurchase $1.5 billion of our common stock, on our weighted average shares outstanding as compared to the prior year periods.

Results for the three months ended September 30, 2021 were affected by certain items that on a net basis increased diluted earnings per share by $0.06 as follows:

• a net pre-tax gain of $45 million (a $42 million gain recorded in other (expense) income, net and a $3 million gain recorded in equity in earnings of equity method investees, net of taxes), or $0.26 per diluted share, primarily due to gains associated with changes in the carrying value of our strategic investments; and
• excess tax benefits associated with stock-based compensation arrangements of $6 million, or $0.04 per diluted share, recorded in income tax expense; partially offset by
• pre-tax amortization expense of $25 million, or $0.15 per diluted share;
• pre-tax charges of $13 million ($7 million in cost of services and $6 million in selling, general and administrative expenses), or $0.08 per diluted share, primarily associated with systems conversions and integration incurred in connection with further restructuring and integrating our business; and
• pre-tax charges of $4 million in selling, general and administrative expenses, or $0.01 per diluted share, primarily due to costs associated with donations, contributions and other financial support through Quest for Health Equity.

Results for the nine months ended September 30, 2021 were affected by certain items that on a net basis increased diluted earnings per share by $1.50 as follows:

• a pre-tax gain recorded in other (expense) income, net of $314 million, or $2.00 per diluted share, on the sale of our 40% ownership interest in Q 2 Solutions ® ("Q 2 Solutions"), our clinical trials central laboratory services joint venture, to IQVIA Holdings, Inc. ("IQVIA"), our joint venture partner (see Note 5 to the interim unaudited consolidated financial statements);
• a net pre-tax gain of $37 million (a $42 million gain recorded in other (expense) income, net, partially offset by $5 million of net charges recorded in equity in earnings of equity method investees), or $0.22 per diluted share, primarily due to gains associated with changes in the carrying value of our strategic investments, partially offset by a non-cash impairment charge to the carrying value of an equity method investment; and
• excess tax benefits associated with stock-based compensation arrangements of $15 million, or $0.11 per diluted share, recorded in income tax expense; partially offset by
• pre-tax amortization expense of $79 million ($77 million in amortization of intangible assets and $2 million in equity in earnings of equity method investees, net of taxes) or $0.46 per diluted share;
• pre-tax charges of $51 million ($26 million in cost of services and $25 million in selling, general and administrative expenses), or $0.30 per diluted share, primarily associated with systems conversions and integration incurred in connection with further restructuring and integrating our business;
• pre-tax charges of $9 million in selling, general and administrative expenses, or $0.04 per diluted share, primarily due to costs associated with donations, contributions and other financial support through Quest for Health Equity; and
• pre-tax charges of $4 million in cost of services, or $0.03 per diluted share, representing the impact of certain items resulting from the COVID-19 pandemic including incremental costs incurred to protect the health and safety of our employees and customers.

Net Revenues

Net revenues for the three months ended September 30, 2022 decreased by 10.4% compared to the prior year period.

DIS revenues for the three months ended September 30, 2022 decreased by 10.5% compared to the prior year period.


29
Table of Contents
For the three months ended September 30, 2022:

• The decrease in revenue compared to the prior year period was driven by a decrease in COVID-19 testing, partially offset by growth in the base business (which excludes COVID-19 testing) and, to a lesser extent, the impact of recent acquisitions. For the three months ended September 30, 2022, recent acquisitions contributed approximately 0.5% to DIS revenues.
• DIS volume decreased by 6.2% compared to the prior year period driven by a decrease in COVID-19 testing, partially offset by growth in the base business and the impact of recent acquisitions, which contributed approximately 0.2% to DIS volume.
• Revenue per requisition decreased by 5.1% compared to prior year period driven in large part by the decrease in COVID-19 molecular testing, and unit price pressure of approximately 0.5%, partially offset by favorable test mix.
• Revenues in the base business (including the impact of recent acquisitions) increased by 5.4% compared to the prior year period.
• Testing volume in the base business (including the impact of recent acquisitions) was up 1.6% compared to the prior year period.
• Revenue per requisition in the base business increased by 3.3% compared to the prior year period primarily due to favorable test mix.

DS revenues for the three months ended September 30, 2022 decreased by 5.9% compared to the prior year period primarily due to lower revenues associated with our risk assessment services offered to the life insurance industry.
Net revenues for the nine months ended September 30, 2022 decreased by 6.1% compared to the prior year period.

DIS revenues for the nine months ended September 30, 2022 decreased by 6.1% compared to the prior year period.

For the nine months ended September 30, 2022:

• The decrease in revenue compared to the prior year period was driven by a decrease in COVID-19 testing, partially offset by growth in the base business and the impact of recent acquisitions. For the nine months ended September 30, 2022, recent acquisitions contributed approximately 0.9% to DIS revenues.
• DIS volume decreased by 2.2% compared to the prior year period driven by a decrease in COVID-19 testing, partially offset by growth in the base business and the impact of recent acquisitions, which contributed approximately 0.8% to DIS volume.
• Revenue per requisition decreased by 4.3% compared to the prior year period driven in large part by the decrease in COVID-19 molecular testing and unit price pressure of approximately 0.5%, partially offset by favorable test mix.
• Revenues in the base business (including the impact of recent acquisitions) increased by 5.2% compared to the prior year period.
• Testing volume in the base business (including the impact of recent acquisitions) was up 3.1% compared to the prior year period.
• Revenue per requisition in the base business increased by 1.7% compared to the prior year period primarily due to favorable test mix.

DS revenues for the nine months ended September 30, 2022 decreased by 7.9% compared to the prior year period primarily due to lower revenues associated with our risk assessment services offered to the life insurance industry.

Cost of Services

Cost of services consists principally of costs for obtaining, transporting and testing specimens as well as facility costs used for the delivery of our services.

For the three months ended September 30, 2022, cost of services decreased by $52 million compared to the prior year period. The decrease was primarily driven by lower expense associated with reduced COVID-19 testing volumes, and $20 million of expense in the prior year period associated with a payment to eligible employees to help offset expenses they incurred as a result of COVID-19. These decreases were partially offset by higher compensation and benefits costs (primarily related to wage increases).


30
Table of Contents
For the nine months ended September 30, 2022, cost of services increased by $14 million compared to the prior year period. The increase was primarily driven by higher compensation and benefits costs (primarily related to wage increases), and additional costs associated with our acquisitions. These increases were partially offset by lower supplies expense associated with reduced COVID-19 testing volumes.
Selling, General and Administrative Expenses ("SG&A")
SG&A consist principally of the costs associated with our sales and marketing efforts, billing operations, credit loss expense and general management and administrative support as well as administrative facility costs.
SG&A increased by $37 million for the three months ended September 30, 2022, compared to the prior year period primarily due to additional costs associated with investments in our strategic growth initiatives and higher compensation and benefits costs (including headcount and wage increases).

SG&A increased by $48 million for the nine months ended September 30, 2022, compared to the prior year period, primarily driven by additional costs associated with investments in our strategic growth initiatives and higher compensation and benefits costs (including headcount and wage increases), partially offset by $42 million of lower costs associated with changes in the value of our deferred compensation obligations.

The changes in the value of our deferred compensation obligations is largely offset by changes in the value of the associated investments, which are recorded in other (expense) income, net. For further details regarding our deferred compensation plans, see Note 17 to the audited consolidated financial statements included in our 2021 Annual Report on Form 10-K.
Amortization Expense
For the three and nine months ended September 30, 2022, amortization expense increased by $2 million and $4 million, respectively, compared to the prior year periods as a result of recent acquisitions.

Other Operating Income, Net

Other operating income, net includes miscellaneous income and expense items and other charges related to operating activities.
For both the three and nine months ended September 30, 2022, other operating income, net includes a $10 million gain from a payroll tax credit under the CARES Act associated with the retention of employees. The three months ended September 30, 2022 also includes a gain associated with the decrease in the fair value of the contingent consideration accrual associated with previous acquisitions.

Interest Expense, Net

For the three and nine months ended September 30, 2022, interest expense, net decreased by $5 million and $8 million, respectively, compared to the prior year periods due to increased interest income resulting from the impact of rising interest rates on our cash and cash equivalents.

Other (Expense) Income, Net

Other (expense) income, net represents miscellaneous income and expense items related to non-operating activities, such as gains and losses associated with investments and other non-operating assets.

For the three months ended September 30, 2022, other (expense) income, net included $6 million of losses associated with investments in our deferred compensation plans.

For the three months ended September 30, 2021, other (expense) income, net included $42 million of gains associated with changes in the carrying value of our strategic investments.


31
Table of Contents
For the nine months ended September 30, 2022, other (expense) income, net included $31 million of losses associated with investments in our deferred compensation plans and $30 million of losses associated with changes in the carrying value of our strategic investments.

For the nine months ended September 30, 2021, other (expense) income, net primarily included a $314 million pre-tax gain on the sale of our 40% ownership interest in Q 2 Solutions, our clinical trials central laboratory services joint venture, to IQVIA, our joint venture partner (see Note 5 to the interim unaudited consolidated financial statements) and $42 million of gains associated with changes in the carrying value of our strategic investments.
Income Tax Expense
Income tax expense for the three months ended September 30, 2022 and 2021 was $81 million and $153 million, respectively. The decrease in income tax expense for the three months ended September 30, 2022 compared to the prior year period was primarily driven by a decrease in income before income taxes and equity in earnings of equity method investees.

Income tax expense for the nine months ended September 30, 2022 and 2021 was $268 million and $483 million, respectively. The decrease in income tax expense for the nine months ended September 30, 2022 compared to the prior year period was primarily driven by a decrease in income before income taxes and equity in earnings of equity method investees.

For the nine months ended September 30, 2022 and 2021, the effective income tax rate was 23.8% and 23.1%, respectively. For the nine months ended September 30, 2021, the effective income tax rate benefited from a lower effective income tax rate, 17.6%, on the gain on the sale of the Company's 40% ownership interest in Q 2 Solutions. In addition, the effective income tax rate benefited from $10 million and $15 million of excess tax benefits associated with stock-based compensation arrangements for the nine months ended September 30, 2022 and 2021, respectively.

Equity in Earnings of Equity Method Investees, Net of Taxes

Equity in earnings of equity method investees, net of taxes decreased for the three months ended September 30, 2022 by $20 million compared to the prior year period primarily due to lower demand for COVID-19 testing services at our diagnostic information services joint venture.

Equity in earnings of equity method investees, net of taxes decreased for the nine months ended September 30, 2022 by $12 million compared to the prior year period primarily due to $14 million of lower equity earnings in the current year period associated with changes in the carrying value of strategic investments of an equity method investee and lower demand for COVID-19 testing services at our diagnostic information services joint venture, partially offset by a non-cash impairment to the carrying value of an equity method investment of $8 million in the prior year period.
Quantitative and Qualitative Disclosures About Market Risk

We address our exposure to market risks, principally the risk of changes in interest rates, through a controlled program of risk management that includes the use of derivative financial instruments. We do not hold or issue derivative financial instruments for speculative purposes. We seek to mitigate the variability in cash outflows that result from changes in interest rates by maintaining a balanced mix of fixed-rate and variable-rate debt obligations. In order to achieve this objective, we have historically entered into interest rate swap agreements. Interest rate swap agreements involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements are recognized as an adjustment to interest expense, net. We believe that our exposures to foreign exchange impacts and changes in commodity prices are not material to our consolidated results of operations, financial position or cash flows.
As of September 30, 2022 and December 31, 2021, the fair value of our debt was estimated at approximately $3.6 billion and $4.4 billion, respectively, principally using quoted prices in active markets and yields for the same or similar types of borrowings, taking into account the underlying terms of the debt instruments. As of September 30, 2022 and December 31, 2021, the estimated fair value (was less than) exceeded the carrying value of the debt by $(354) million and $403 million, respectively. A hypothetical 10% increase in interest rates (representing 52 basis points as of September 30, 2022 and 23 basis points as of December 31, 2021) would potentially reduce the estimated fair value of our debt by approximately $124 million and $89 million as of September 30, 2022 and December 31, 2021, respectively.

Borrowings under our secured receivables credit facility and our senior unsecured revolving credit facility are subject to variable interest rates. As of September 30, 2022, interest on our secured receivables credit facility is based on either commercial paper rates for highly rated issuers, or London Interbank Offered Rate ("LIBOR"), plus a spread. As of

32
Table of Contents
September 30, 2022, interest on our senior unsecured revolving credit facility is based on certain published rates plus an applicable margin based on changes in our public debt ratings. As such, our borrowing cost under this credit arrangement is subject to fluctuations in interest rates and changes in our public debt ratings. As of September 30, 2022, the borrowing rates under these debt instruments were: for our secured receivables credit facility, commercial paper rates for highly-rated issuers or LIBOR, plus a spread of 0.725% to 0.80%; and for our senior unsecured revolving credit facility, LIBOR plus 1.00%. As of September 30, 2022, there were no borrowings outstanding under either our $600 million secured receivables credit facility or our $750 million senior unsecured revolving credit facility. During October 2022, we amended the secured receivables credit facility and, subsequent to the amendment, borrowing rates are based on commercial paper rates for highly rated issuers, or the Term Secured Overnight Financing Rate ("Term SOFR"), plus a spread of 0.725% to 0.80%. In conjunction with the amendment we decreased the aggregate borrowing capacity to $525 million.

A hypothetical 10% change to the variable rate component of our variable rate indebtedness would not materially change our annual interest expense.

For further details regarding our outstanding debt, see Note 15 to the interim unaudited consolidated financial statements and Note 13 to the audited consolidated financial statements included in our 2021 Annual Report on Form 10-K. For details regarding our financial instruments and hedging activities, see Note 8 to the interim unaudited consolidated financial statements and Note 15 to the audited consolidated financial statements included in our 2021 Annual Report on Form 10-K.

Risk Associated with Investment Portfolio

Our investment portfolio primarily includes equity investments comprised mostly of strategic holdings in companies concentrated in the life sciences and healthcare industries. Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) with readily determinable fair values are measured at fair value in prepaid expenses and other current assets in our consolidated balance sheet with changes in fair value recorded in current earnings in our consolidated statement of operations. Equity investments that do not have readily determinable fair values (which consist of investments in preferred and common shares of private companies) are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes. We regularly evaluate equity investments that do not have readily determinable fair values to determine if there are any indicators that the investments are impaired. The carrying value of our equity investments that do not have readily determinable fair values was $4 million as of September 30, 2022.
We do not hedge our equity price risk. As of September 30, 2022, a 10% change in the fair values of our equity investments with readily determinable fair values would have impacted our consolidated income before income taxes and equity in earnings of equity method investees by $1 million. The impact of an adverse movement in equity prices on our holdings in privately held companies cannot be easily quantified, as our ability to realize returns on investments depends on, among other things, the enterprises’ ability to raise additional capital or derive cash inflows from continuing operations or through liquidity events such as initial public offerings, mergers or private sales.

In conjunction with the preparation of our September 30, 2022 financial statements, we considered whether the carrying values of our investments were impaired and concluded that no such impairment existed.

Liquidity and Capital Resources
Nine Months Ended September 30,
2022 2021 Change
(dollars in millions)
Net cash provided by operating activities $ 1,384 $ 1,752 $ (368)
Net cash (used in) provided by investing activities (369) 248 (617)
Net cash used in financing activities (1,187) (2,171) 984
Net change in cash and cash equivalents and restricted cash $ (172) $ (171) $ (1)
Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly-liquid short-term investments with original maturities, at the time of acquisition, of three months or less. Cash and cash equivalents as of September 30, 2022 totaled $700 million, compared to $872 million as of December 31, 2021.


33
Table of Contents
As of September 30, 2022, approximately 5% of our $700 million of consolidated cash and cash equivalents were held outside of the United States.

Cash Flows from Operating Activities

Net cash provided by operating activities for the nine months ended September 30, 2022 and 2021 was $1,384 million and $1,752 million, respectively. The $368 million decrease in net cash provided by operating activities for the nine months ended September 30, 2022, compared to the prior year period was primarily a result of:

• lower operating income in 2022 as compared to 2021; and
• higher payments associated with an additional payroll cycle in 2022 as compared to 2021; partially offset by
• a $335 million decrease in income tax payments in 2022 as compared to 2021.
Days sales outstanding, a measure of billing and collection efficiency, was 47 days as of September 30, 2022, 48 days as of December 31, 2021 and 47 days as of September 30, 2021.

Cash Flows from Investing Activities

Net cash (used in) provided by investing activities for the nine months ended September 30, 2022 and 2021 was $(369) million and $248 million, respectively. This $617 million change in net cash (used in) provided by investing activities for the nine months ended September 30, 2022, compared to the prior year period was primarily a result of $755 million of net cash proceeds received in 2021 from the sale of our 40% ownership interest in Q 2 Solutions, partially offset by a $145 million decrease in net cash paid for business acquisitions.

Cash Flows from Financing Activities

Net cash used in financing activities for the nine months ended September 30, 2022 and 2021 was $1,187 million and $2,171 million, respectively. This $984 million decrease in net cash used in financing activities for the nine months ended September 30, 2022, compared to the prior year period was primarily a result of a $963 million decrease in repurchases of our common stock.

During both the nine months ended September 30, 2022 and 2021, there were no borrowings or repayments under our secured receivables credit facility or senior unsecured revolving credit facility.

Dividend Program
During each of the three quarters of 2022, our Board of Directors declared a quarterly cash dividend of $0.66 per common share. During each of the four quarters of 2021, our Board of Directors declared a quarterly cash dividend of $0.62 per common share.
Share Repurchase Program

In February 2022, our Board of Directors increased the size of our share repurchase program by $1 billion. As of September 30, 2022, $746 million remained available under our share repurchase authorization. The share repurchase authorization has no set expiration or termination date.

Share Repurchases

For the nine months ended September 30, 2022, we repurchased 7.1 million shares of our common stock for $950 million.

For the nine months ended September 30, 2021, we repurchased 12.5 million shares of our common stock for $1.6 billion, including 9.1 million shares repurchased under ASRs.

For further details regarding our share repurchases, see Note 9 to the interim unaudited consolidated financial statements.


34
Table of Contents
Equity Method Investees

Our equity method investees primarily consist of a diagnostic information services joint venture and an investment in a fund that purchases strategic holdings in private companies in the healthcare industry. Such investees are accounted for under the equity method of accounting. Our investment in equity method investees is less than 5% of our consolidated total assets. Our proportionate share of income before income taxes associated with our equity method investees is less than 5% of our consolidated income before income taxes and equity in earnings of equity method investees. We have no material unconditional obligations or guarantees to, or in support of, our equity method investees and their operations.

In conjunction with the preparation of our September 30, 2022 financial statements, we considered whether the carrying values of our equity method investments were impaired and concluded that no such impairment existed.

Requirements and Capital Resources

We estimate that we will invest approximately $400 million during 2022 for capital expenditures, to support and grow our existing operations, principally related to investments in information technology, laboratory equipment and facilities, including laboratory automations and footprint optimization; and in our advanced diagnostics and consumer growth strategies.

As of September 30, 2022, we had $1.3 billion of borrowing capacity available under our existing credit facilities, including $530 million available under our secured receivables credit facility and $750 million available under our senior unsecured revolving credit facility. There were no borrowings under these credit facilities as of September 30, 2022. In support of our risk management program, $70 million in letters of credit under the secured receivables credit facility were outstanding as of September 30, 2022. During October 2022, we amended our secured receivables credit facility and decreased the aggregate borrowing capacity under the secured receivables credit facility to $525 million. The amended secured receivables credit facility includes a $425 million loan commitment, half of which matures in October 2023 and half of which matures in October 2024. Additionally, the amended secured receivables credit facility includes a $100 million letter of credit facility which matures in October 2024. The senior unsecured revolving credit facility matures in November 2026. For further details regarding our credit facilities, see Note 13 to the audited consolidated financial statements in our 2021 Annual Report on Form 10-K and Note 15 to the interim unaudited consolidated financial statements.

Our secured receivables credit facility is subject to customary affirmative and negative covenants, and certain financial covenants with respect to the receivables that comprise the borrowing base and secure the borrowings under the facility. Our senior unsecured revolving credit facility is also subject to certain financial covenants and limitations on indebtedness. As of September 30, 2022, we were in compliance with all such applicable financial covenants.

We have assessed the impact of the cessation of LIBOR and have identified and evaluated financial instruments and other contracts that refer to LIBOR. Our underlying exposure to LIBOR includes our senior unsecured revolving credit facility (see discussion above) under which we had no outstanding borrowings as of September 30, 2022. During October 2022, we amended our secured receivables credit facility and, subsequent to the amendment, borrowing rates are based on commercial paper rates for highly rated issuers, or the Term SOFR, plus a spread of 0.725% to 0.80%. We expect to be able to transition all LIBOR based instruments and contracts to an alternative reference rate on or before the cessation of LIBOR and we do not believe that the cessation of LIBOR, or its replacement with an alternative reference rate or rates, will have a material impact on us.

We believe that our cash and cash equivalents and cash from operations, together with our borrowing capacity under our credit facilities, will provide sufficient financial flexibility to fund seasonal and other working capital requirements, capital expenditures, debt service requirements and other obligations, cash dividends on common shares, share repurchases and additional growth opportunities for the foreseeable future. However, should it become necessary, we believe that our credit profile should provide us with access to additional financing in order to fund normal business operations, make interest payments, fund growth opportunities and satisfy upcoming debt maturities.


35
Table of Contents
Forward-Looking Statements
Some statements and disclosures in this document are forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could cause our plans and expectations, including actual results, to differ materially from the forward-looking statements. Risks and uncertainties that may affect our future results include, but are not limited to, impacts of the COVID-19 pandemic and measures taken in response, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in our most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk
See Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations."

Item 4.    Controls and Procedures

Management, including our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended). Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this quarterly report.

During the third quarter of 2022, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended) that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


PART II - OTHER INFORMATION

Item 1.    Legal Proceedings
See Note 11 to the interim unaudited consolidated financial statements for information regarding the status of legal proceedings involving the Company.


36
Table of Contents
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

The table below sets forth the information with respect to purchases made by or on behalf of the Company of its common stock during the third quarter of 2022.

ISSUER PURCHASES OF EQUITY SECURITIES
Period Total Number of
Shares
Purchased 		Average Price
Paid per Share 		Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs
Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the Plans
or Programs
(in thousands)
July 1, 2022 – July 31, 2022
Share Repurchase Program (A) 223,663 $ 134.13 223,663 $ 1,115,906
Employee Transactions (B) — $ — N/A N/A
August 1, 2022 – August 31, 2022
Share Repurchase Program (A) 1,235,212 $ 134.98 1,235,212 $ 949,174
Employee Transactions (B) 1,321 $ 139.95 N/A N/A
September 1, 2022 – September 30, 2022
Share Repurchase Program (A) 1,625,739 $ 125.03 1,625,739 $ 745,908
Employee Transactions (B) — $ — N/A N/A
Total
Share Repurchase Program (A) 3,084,614 $ 129.68 3,084,614 $ 745,908
Employee Transactions (B) 1,321 $ 139.95 N/A N/A

(A) In February 2022, our Board of Directors increased the size of our share repurchase program by $ 1 billion. Since the share repurchase program’s inception in May 2003, our Board of Directors has authorized $12 billion of share repurchases of our common stock through September 30, 2022. The share repurchase authorization has no set expiration or termination date.

(B) Includes: (1) shares delivered or attested to in satisfaction of the exercise price and/or tax withholding obligations by holders of stock options (granted under the Company’s Amended and Restated Employee Long-Term Incentive Plan) who exercised options; and (2) shares withheld (under the terms of grants under the Amended and Restated Employee Long-Term Incentive Plan) to offset tax withholding obligations that occur upon the delivery of outstanding common shares underlying restricted stock units and performance share units.



37
Table of Contents
Item 6. Exhibits

Exhibits:
3.1
10.1
22
31.1
31.2
32.1
32.2
101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH Inline XBRL Taxonomy Extension Schema Document - dgx-20220930.xsd
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document - dgx-20220930_cal.xml
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document - dgx-20220930_def.xml
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document - dgx-20220930_lab.xml
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document - dgx-20220930_pre.xml
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

38
Table of Contents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
October 21, 2022
Quest Diagnostics Incorporated
By /s/ Stephen H. Rusckowski
Stephen H. Rusckowski
Chairman, Chief Executive Officer
and President
By /s/ Sam Samad
Sam Samad
Executive Vice President and
Chief Financial Officer


39
TABLE OF CONTENTS